Strategic partnerships Leverage LDC’s established collaborations with major pharma and translational centers (AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi-Sankyo, Roche, J&J Innovation, Sotio) and academic partners to identify co-development or licensing opportunities and to position your approach as a preferred collaborator in immune-oncology, rare diseases, and metabolic disease programs.

Technology leadership Position LDC as a turnkey small molecule discovery partner with strengths in Automation & Screening, Cellular Biology, Pharmacology, Medicinal Chemistry and therapeutic Antibody Discovery to offer end-to-end hit generation, lead optimization, and early proof-of-concept services to academic and biotech clients seeking rapid progression.

Pipeline expansion Target opportunities related to KyDo technology collaborations and recent campus partnerships (TU Dortmund, IfADo, Taros Chemicals) to access early-stage programs with translational potential, offering joint development programs, milestone-driven deals, and access to unique screening platforms.

Global funding signals Capitalize on LDC’s international collaborations (McGill University, INSERM, Semmelweis University) and public-private consortiums to pursue grant-enabled co-development, milestone financing, or sponsored research arrangements that can de-risk early discovery projects for potential buyers.

Commercial fit With a revenue range indicating active client delivery and a mid-sized team, propose flexible engagement models (out-licensing, milestone-based partnerships, or fee-for-service plus success royalties) tailored to academia, biotech startups, and mid-size pharma seeking accelerated lead generation and proof-of-concept validation.